RxDoctor Payments Data

Caroline Parra

Family · San Jose, CANPI 1023037421

Payments from drug & device makers

$2,722in general payments, 2019–2025

Across 132 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$604
  • Novo Nordisk$330
  • Lilly USA, LLC$293
  • Bayer$282
  • Boehringer Ingelheim$262
  • Abbott$218
  • plus $733 from 14 others

What the payments were for

  • Food & beverage$2,722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,722 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol40$41,379
JardianceEmpagliflozin20$21,755
JanuviaSitagliptin Phosphate18$16,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,038
LinzessLinaclotide11$6,835
Celecoxib70$3,159
Rosuvastatin Calcium90$1,663
Levothyroxine Sodium91$1,588
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide80$1,293
Losartan Potassium106$1,063
Atorvastatin Calcium97$962
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide16$957
Diclofenac Sodium85$862
Albuterol Sulfate HfaAlbuterol Sulfate31$815
Amlodipine Besylate106$798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$115$41,37940 claims
Boehringer IngelheimJardiance$262$21,75520 claims
MerckJanuvia$34$16,11118 claims
GSKTrelegy Ellipta$604$12,03819 claims
AbbVieLinzess$78$6,83511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →